RECURA™ Peer Reviewed Science Published in the International Journal of Pharmaceutical Compounding
AUSTIN, March 2, 2016/– Humco, a diversified global pharmaceutical company, announced today the publication of the positive results of RECURA™ Topical Cream in the January/February 2016 issue of the International Journal of Pharmaceutical Compounding (IJPC). The aim of this study was to use in vitro nail models to investigate the potential of pharmaceutically compounded RECURA™ containing either fluconazole or miconazole for the treatment of onychomycosis in comparison to two commercial comparators (Jublia and a Penlac generic).
Initially, a modified Franz cell was used, where sections of human nail served as the barrier through which drug penetrated into an agar-filled chamber infected with dermatophytes. A second study was performed using a novel infected nail model where dermatophytes grew into human nail and adenosine triphosphate levels were used as biological marker for antimicrobial activity.
The novel enhancing system RECURA™ increased the permeation of both existing drugs through human nail sections mounted in a modified Franz cell. Furthermore, the infected nail model also confirmed that the system also enhanced the permeation through infected nail resulting in a decrease in adenosine triphosphate levels superior (P ≤0.05) to Penlac generic and equivalent (P >0.05) to the commercial comparator Jublia.
This study demonstrated that with the use of a novel permeation-enhancing formulation base, RECURA™ enhances delivery of miconazole and fluconazole when applied ungually such that the efficacy was equivalent or superior to commercial comparators. Such a topically applied system has the possibility of overcoming the systemic side effects of antifungals when taken orally.
For more information on RECURA™ and the full published IJPC study, please visit Humco’s website at www.humco.com.
Humco, founded in 1872, is a diversified global pharmaceutical company. Humco is focused on developing, manufacturing and commercializing innovative pharmaceuticals and high-quality over-the-counter (OTC) medicines for patients around the world.
With headquarters in Austin, TX, Humco serves over 45,000 pharmacies through its Pharmaceutical Segment and its Consumer OTC Products franchise. The Company is anchored by its leading non-sterile compounding delivery vehicles, including topical and transdermal creams, syrups, and suspensions. Humco also serves consumers through its established and diverse Consumer OTC Products business of over 160 items with product placement in all major drug, food, and mass-market retail chains, along with independent, locally owned pharmacies.
Humco’s leading team of professionals have strong expertise ranging from product development to commercialization in the Company’s state-of-the-art FDA registered, cGMP compliant facilities.
With a presence in approximately 20 countries, Humco is committed to working with pharmacists, physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Humco’s website at www.humco.com.
+1 (512) 474-7400
+1 (903) 334-6206
SOURCE: Humco, Inc.